Published in Prog Neurobiol on October 09, 2015
The Locus Coeruleus: Essential for Maintaining Cognitive Function and the Aging Brain. Trends Cogn Sci (2016) 0.83
Diffusion tensor imaging of the substantia nigra in Parkinson's disease revisited. Hum Brain Mapp (2016) 0.83
Role of iron in neurodegenerative diseases. J Neural Transm (Vienna) (2016) 0.79
Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci (2017) 0.79
The Neuromelanin-related T2* Contrast in Postmortem Human Substantia Nigra with 7T MRI. Sci Rep (2016) 0.77
Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease. J Neurochem (2016) 0.77
Alpha-synuclein and iron: two keys unlocking Parkinson's disease. J Neural Transm (Vienna) (2017) 0.76
Midbrain Gene Screening Identifies a New Mesoaccumbal Glutamatergic Pathway and a Marker for Dopamine Cells Neuroprotected in Parkinson's Disease. Sci Rep (2016) 0.76
Parkinson's Disease: The Mitochondria-Iron Link. Parkinsons Dis (2016) 0.76
Dentate nucleus iron deposition is a potential biomarker for tremor-dominant Parkinson's disease. NMR Biomed (2016) 0.76
In vivo detection of lateral-ventral tier nigral degeneration in Parkinson's disease. Hum Brain Mapp (2017) 0.76
Excessive early-life dietary exposure: a potential source of elevated brain iron and a risk factor for Parkinson's disease. NPJ Parkinsons Dis (2017) 0.76
Metals and Neurodegeneration. F1000Res (2016) 0.76
Uses, misuses, new uses and fundamental limitations of magnetic resonance imaging in cognitive science. Philos Trans R Soc Lond B Biol Sci (2016) 0.75
Utility of susceptibility-weighted imaging in Parkinson's disease and atypical Parkinsonian disorders. Transl Neurodegener (2016) 0.75
Characterization of a Novel Monoclonal Antibody against Human Mitochondrial Ferritin and Its Immunohistochemical Application in Human and Monkey Substantia Nigra. Acta Histochem Cytochem (2017) 0.75
Neuromelanin, one of the most overlooked molecules in modern medicine, is not a spectator. Neural Regen Res (2017) 0.75
New Insights into the Crosstalk between NMDARs and Iron: Implications for Understanding Pathology of Neurological Diseases. Front Mol Neurosci (2017) 0.75
Pool size ratio of the substantia nigra in Parkinson's disease derived from two different quantitative magnetization transfer approaches. Neuroradiology (2017) 0.75
Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care. J Magn Reson Imaging (2017) 0.75
Subcellular compartmentalisation of copper, iron, manganese, and zinc in the Parkinson's disease brain. Metallomics (2017) 0.75
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med (1991) 16.01
Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science (2004) 15.91
Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci (2006) 12.23
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci (2007) 11.24
Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science (2002) 9.90
Structure and function of the blood-brain barrier. Neurobiol Dis (2009) 7.64
Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res (2004) 7.06
Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology (1988) 6.79
Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell (2012) 6.31
Two to tango: regulation of Mammalian iron metabolism. Cell (2010) 5.45
Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci (2004) 5.37
Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci (2001) 5.32
The effect of age on the non-haemin iron in the human brain. J Neurochem (1958) 4.83
Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta (2003) 4.78
Mitochondria, oxidative stress and cell death. Apoptosis (2007) 4.29
Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet (2006) 4.01
Forging a field: the golden age of iron biology. Blood (2008) 3.83
Blood-brain barrier: ageing and microvascular disease--systematic review and meta-analysis. Neurobiol Aging (2007) 3.63
Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol (1999) 3.63
Dopamine covalently modifies and functionally inactivates parkin. Nat Med (2005) 3.43
A medicinal chemist's guide to molecular interactions. J Med Chem (2010) 3.39
Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet (2005) 3.29
Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest (2008) 3.23
Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem (2001) 3.13
Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature (1988) 3.12
Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu Rev Nutr (2008) 2.98
Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest (2008) 2.91
Protein carbonylation in human diseases. Trends Mol Med (2003) 2.82
Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology (1985) 2.58
Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol (2005) 2.54
The physical and chemical properties of eumelanin. Pigment Cell Res (2006) 2.53
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain (1991) 2.52
The labile iron pool: characterization, measurement, and participation in cellular processes(1). Free Radic Biol Med (2002) 2.51
Lipid peroxidation of membrane phospholipids generates hydroxy-alkenals and oxidized phospholipids active in physiological and/or pathological conditions. Chem Phys Lipids (2008) 2.49
Aromatic rings in chemical and biological recognition: energetics and structures. Angew Chem Int Ed Engl (2011) 2.48
Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol (2008) 2.46
The protective role of melanin against UV damage in human skin. Photochem Photobiol (2008) 2.45
The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci (2006) 2.44
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem (1989) 2.44
Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev (2004) 2.42
Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol (2001) 2.36
Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J (2012) 2.36
Ascorbate regulation and its neuroprotective role in the brain. Trends Neurosci (2000) 2.36
Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry (2002) 2.29
Biology of amyloid: structure, function, and regulation. Structure (2010) 2.24
Advances in the genetics of Parkinson disease. Nat Rev Neurol (2013) 2.21
Structure, function, and mechanism of ribonucleotide reductases. Biochim Biophys Acta (2004) 2.14
Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord (1998) 2.12
Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm (1988) 2.10
Structures for amyloid fibrils. FEBS J (2005) 1.98
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem (1989) 1.94
Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc Natl Acad Sci U S A (2008) 1.93
Iron deficiency alters brain development and functioning. J Nutr (2003) 1.93
Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J Neurochem (1992) 1.91
Oligodendrocytes and myelination: the role of iron. Glia (2009) 1.90
Copper active sites in biology. Chem Rev (2014) 1.90
Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci U S A (2000) 1.81
Advanced chemical methods in melanin determination. Pigment Cell Res (2002) 1.78
A timeline for Parkinson's disease. Parkinsonism Relat Disord (2009) 1.75
Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol (2007) 1.72
Iron trafficking inside the brain. J Neurochem (2007) 1.71
The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry (1991) 1.68
Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat Res (2003) 1.66
Photoprotection by melanin. J Photochem Photobiol B (1991) 1.66
Melanin in human irides of different color and age of donors. Pigment Cell Res (2005) 1.65
Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem J (1997) 1.61
Microglia in the aging brain. J Neuropathol Exp Neurol (2006) 1.60
Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. J Neurosci Res (1990) 1.60
High-resolution calcium mapping of the endoplasmic reticulum-Golgi-exocytic membrane system. Electron energy loss imaging analysis of quick frozen-freeze dried PC12 cells. Mol Biol Cell (1997) 1.59
Biogenesis of iron-sulfur clusters in mammalian cells: new insights and relevance to human disease. Dis Model Mech (2012) 1.59
Wilson disease: description of 282 patients evaluated over 3 decades. Medicine (Baltimore) (2007) 1.59
The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci U S A (2004) 1.59
Iron in parkinsonian and control substantia nigra--a Mössbauer spectroscopy study. Mov Disord (1996) 1.57
Comparison of structural and chemical properties of black and red human hair melanosomes. Photochem Photobiol (2005) 1.54
Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci (2003) 1.51
Characterization of a novel brain-derived microglial cell line isolated from neonatal rat brain. Glia (2001) 1.51
Brain iron metabolism. Semin Pediatr Neurol (2006) 1.51
Distinct monoamine oxidase A and B populations in primate brain. Science (1985) 1.50
Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport (1999) 1.49
Chemistry of mixed melanogenesis--pivotal roles of dopaquinone. Photochem Photobiol (2008) 1.47
Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J Biol Chem (2005) 1.47
Iron metabolism in the CNS: implications for neurodegenerative diseases. Nat Rev Neurosci (2013) 1.46
Transport of iron in the blood-brain-cerebrospinal fluid system. J Neurochem (1997) 1.45
An update on iron physiology. World J Gastroenterol (2009) 1.44
Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. FASEB J (2003) 1.43
The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu Rev Neurosci (1997) 1.42
α-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol (2012) 1.42
Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. Neurobiol Dis (2012) 1.39
Increased nigral iron content in postmortem parkinsonian brain. Lancet (1987) 1.39
Epidermal "turnover time"--a re-examination. Br J Dermatol (1972) 1.38
Neuronal pigmented autophagic vacuoles: lipofuscin, neuromelanin, and ceroid as macroautophagic responses during aging and disease. J Neurochem (2008) 1.37
Metal-ion interactions and the structural organization of Sepia eumelanin. Pigment Cell Res (2005) 1.35
The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol (2014) 1.35
Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Neurotox Res (2009) 1.35
Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alpha-synuclein. J Biol Chem (2007) 1.34
Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease. J Neurochem (2013) 1.34
Iron deficiency: differential effects on monoamine transporters. Nutr Neurosci (2005) 1.34
The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol (2014) 1.35
Protective and toxic roles of dopamine in Parkinson's disease. J Neurochem (2014) 1.17
Melanins and melanogenesis: from pigment cells to human health and technological applications. Pigment Cell Melanoma Res (2015) 0.92
Engineered nanoparticles. How brain friendly is this new guest? Prog Neurobiol (2014) 0.84
Aerobic photoreactivity of synthetic eumelanins and pheomelanins: generation of singlet oxygen and superoxide anion. Pigment Cell Melanoma Res (2016) 0.78
Photodynamic Inactivation of Candida albicans with Imidazoacridinones: Influence of Irradiance, Photosensitizer Uptake and Reactive Oxygen Species Generation. PLoS One (2015) 0.77
Redox Active Transition Metal ions Make Melanin Susceptible to Chemical Degradation Induced by Organic Peroxide. Cell Biochem Biophys (2017) 0.75
Photodegradation of Eumelanin and Pheomelanin and Its Pathophysiological Implications. Photochem Photobiol (2017) 0.75
Potassium iodide potentiates antimicrobial photodynamic inactivation mediated by Rose Bengal: in vitro and in vivo studies. Antimicrob Agents Chemother (2017) 0.75